Orris

i am md pediatrics currently doing fellowship in pediatric rheuematology. tell me in detail about diagnosis criteria classification and clinical feature of sle in detail based on standard textbooks and latest guidelines

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"systemic lupus erythematosus"[MeSH Terms] AND "classification criteria"

Finding Sources
Reading File
Searching PubMed

"lupus erythematosus" AND "pediatric" AND "classification"

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Searching PubMed

"childhood-onset systemic lupus erythematosus" AND "clinical features"

Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Loading Image
Reading File
A few high-yield clinical pearls specifically for your fellowship practice:
  1. EULAR/ACR 2019 vs SLICC 2012 in pSLE: The 2019 criteria are more specific but require ANA ≥1:80 as a mandatory entry criterion - this is rarely a problem in pediatric SLE (>95% ANA positive), but early-onset or monogenic forms may be ANA-negative, making SLICC 2012 more inclusive and practically useful.
  2. Anti-dsDNA fluctuates with disease activity - useful for monitoring flares, especially renal. Anti-Sm is highly specific but does NOT track activity.
  3. Complement consumption pattern (falling C3/C4 + rising anti-dsDNA) is the most reliable combination for predicting lupus nephritis flare.
  4. Seronegative SLE (~5% anti-dsDNA negative, ~5% ANA negative): Do not dismiss SLE on serology alone if the clinical picture is convincing.
  5. Macrophage Activation Syndrome must be actively ruled out in any cSLE patient with fever, cytopenias, hyperferritinemia (>500 ng/mL, especially >10,000), and hepatosplenomegaly - it is a disease-defining emergency.
  6. Psychosocial screening (anxiety, depression) is now recommended longitudinally in cSLE as per 2025-2026 literature (Valente Soto et al., Lupus 2026; PMID 41665227).

ok now lets move on to treatment and management

Summarising Conversation
Reading File
Finding Sources
Finding Sources
Searching PubMed

"systemic lupus erythematosus" AND "treatment" AND "guidelines"

Reading File
Reading File
Reading File
Reading Article
Reading File
Reading File
Searching PubMed

"lupus nephritis" AND "voclosporin OR belimumab OR obinutuzumab"

Reading Article
Reading Article
Reading File
Reading File
Reading File
High-yield fellowship pearls for practice:
  1. Voclosporin vs tacrolimus in LN: Voclosporin has a flat pharmacokinetic profile - no need for drug level monitoring, unlike tacrolimus. This makes it practically easier to use. However it is not yet approved in children.
  2. Obinutuzumab vs rituximab: Obinutuzumab is a type II anti-CD20 that depletes B cells more completely and durably than rituximab (type I). The REGENCY Phase III (NEJM 2025) is a landmark trial - it's the first positive Phase III trial for a B-cell depleting agent in LN. EULAR 2025 LN guidelines now include it.
  3. The "steroid minimization revolution": The EULAR 2023 update fundamentally shifted the approach - high-dose GC protocols are being replaced. The obinutuzumab trial used prednisone ≤7.5 mg/day by week 12 and ≤5 mg/day by week 24 as a standard arm and still showed excellent response, validating low-GC approaches.
  4. DOACs in APS: The TRAPS trial (rivaroxaban) and RAPS trial showed inferiority to warfarin in triple-positive aPL and arterial thrombosis. For high-risk aPL profiles, warfarin remains standard. DOACs are only considered in low-risk aPL profiles where warfarin cannot be used.
  5. CAR-T in SLE: Early case series from Germany (Mackensen et al., 2022) showed sustained drug-free remission in refractory SLE after CD19-directed CAR-T. This is a paradigm-shifting concept - "resetting" the immune system. Not yet standard care but watch this space.
This is a shared conversation. Sign in to Orris to start your own chat.